Astria Therapeutics, Inc. (ATXS) got here out with a quarterly lack of $0.55 per share versus the Zacks Consensus Estimate of a lack of $0.41. This compares to a lack of $0.42 per share a yr in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of -34.15%. 1 / 4 in the past, it was anticipated that this firm would publish a lack of $0.61 per share when it really produced a lack of $0.57, delivering a shock of +6.56%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
Astria Therapeutics, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $0.71 million for the quarter ended September 2025, lacking the Zacks Consensus Estimate by 95.59%. This compares to zero revenues a yr in the past.
The sustainability of the inventory’s speedy value motion primarily based on the recently-released numbers and future earnings expectations will principally rely on administration’s commentary on the earnings name.
Astria Therapeutics shares have added about 39.9% because the starting of the yr versus the S&P 500’s achieve of 16.4%.
What’s Subsequent for Astria Therapeutics?
Whereas Astria Therapeutics has outperformed the market up to now this yr, the query that involves traders’ minds is: what’s subsequent for the inventory?
There are not any straightforward solutions to this key query, however one dependable measure that may assist traders handle that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified currently.
Empirical analysis reveals a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested ranking software just like the Zacks Rank, which has a powerful monitor document of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for Astria Therapeutics was combined. Whereas the magnitude and path of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in keeping with the market within the close to future. You possibly can see the whole record of at present’s Zacks #1 Rank (Robust Purchase) shares right here.
Will probably be fascinating to see how estimates for the approaching quarters and the present fiscal yr change within the days forward. The present consensus EPS estimate is -$0.59 on $2 million in revenues for the approaching quarter and -$2.09 on $17 million in revenues for the present fiscal yr.
Buyers needs to be conscious of the truth that the outlook for the business can have a fabric influence on the efficiency of the inventory as properly. When it comes to the Zacks Trade Rank, Medical – Biomedical and Genetics is at the moment within the prime 34% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One different inventory from the identical business, Aytu BioPharma Inc. (AYTU), is but to report outcomes for the quarter ended September 2025. The outcomes are anticipated to be launched on November 13.
This firm is anticipated to publish quarterly lack of $0.06 per share in its upcoming report, which represents a year-over-year change of +70%. The consensus EPS estimate for the quarter has remained unchanged over the past 30 days.
Aytu BioPharma Inc.’s revenues are anticipated to be $12.62 million, down 23.8% from the year-ago quarter.
Ought to You Put money into Astria Therapeutics, Inc. (ATXS)?
Earlier than you put money into Astria Therapeutics, Inc. (ATXS), wish to know the perfect shares to purchase for the subsequent 30 days? Try Zacks Funding Analysis for our free report on the 7 greatest shares to purchase.
Zacks Funding Analysis has been dedicated to offering traders with instruments and unbiased analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a median achieve of +24.08% per yr. (These returns cowl a interval from January 1, 1988 by Could 6, 2024.)
Astria Therapeutics, Inc. (ATXS) : Free Inventory Evaluation Report
Aytu BioPharma Inc. (AYTU) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
